로딩 중…
StockDiggingStockDigging

Optipharm.CO.,LTD

153710· KOSDAQ
₩4,575-2.35%
2026-06-19

Price Chart

Optipharm.CO.,LTD-6.06%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap67.12B KRW
Revenue22.79B KRW
Net Income-343.3M KRW
Total Assets39.58B KRW
Net Assets24.76B KRW
Employees77
Value
P/B2.71x
P/S2.95x
EV/EBITDA725.52x
FCF Yield-6.05%
Profitability
ROE-1.39%
ROA-0.87%
Op. Margin0.39%
Revenue Growth9.01%
Financial Health
Debt Ratio159.82%
Total Debt0 KRW
FCF-4.06B KRW
Cash2.22B KRW
Current Ratio1.17x
Net Debt/EBITDA-24.86x
Performance
1Y Return-6.06%
1M Return-8.86%
From 52W High-26.80%
1Y MDD-29.03%
Trading
Volume5,057 shares
Foreign Own.1.13%
Per Share
EPS-144 KRW
BPS1,688 KRW

Company Info

CEO 김현일
Employees 77
Founded 2000
HQ 충청북도 청주시, KR

OptiPharm, established in 2000 and listed on KOSDAQ in 2018, specializes in animal-related businesses, including disease diagnosis, pharmaceuticals, and bacteriophage. Since 2006, it has developed an independent disease appraisal system and diagnostic products. Leveraging original technologies like transgenic technology and animal-related infrastructure, the company is expanding into human-related ventures such as bacteriophage-based disease treatments and xenotransplantation development.